Abstract
Merkel cell cancer (MCC) is a rare neuroendocrine skin tumor characterized by uncontrolled growth of Merkel cells located in the basal layer of the epidermis with aggressive clinical behavior. Tumor malignancy is predominantly associated with Merkel cell polyomavirus.
This tumor is often mistaken for amelanotic melanoma. In addition, it progresses rapidly and its lethality is almost double compared to melanoma.
Its incidence has increased dramatically in recent decades, currently reaching 2-4 cases per one million inhabitants in the US and Europe. Only 26% of patients survive more than two years without treatment.
Its prognosis depends on both the location and stage of the disease. In addition to adjuvant radiotherapy and chemotherapy, avelumab immunotherapy (Bavencio(R)) is now available in the MCC stage IV.